Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Type 2 diabetes
Biotech
Novo expands pivotal program after amycretin shines in diabetes
After posting phase 2 data, Novo has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity prospect.
Nick Paul Taylor
Nov 25, 2025 7:44am
FDA clears Dexcom's basal dosing software for Type 2 diabetes
Nov 19, 2025 9:45am
Lilly pads oral GLP-1 case with pair of phase 3 diabetes wins
Oct 15, 2025 9:48am
FDA clears Biolinq's color-coded sensor patch for glucose ranges
Sep 29, 2025 11:30am
Sparrow flits forward with $95M for midstage diabetes asset
Sep 24, 2025 11:22am
Lilly rounds out orforglipron data ahead of obesity filings
Sep 17, 2025 9:00am
